Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
RLYB(NASDAQ:RLYB) NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced that it received an equity milestone payment of $12.5 million from Recursion. The milestone payment was triggered by the initiation of additional preclinical studies for REV102, an investigational ENPP1 inhibitor in development for the treatment of hypophosphatasia
Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
RLYBNEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today reported financial results for the second quarter ended June 30, 2025, and provided an update on recent company developments. “The second quarter marked a pivotal step forward as we advanced our lead program, RLYB116, into a confirmatory PK/PD study, which is an important mi
Rallybio Initiates Dosing In Phase 1 Confirmatory PK/PD Study Evaluating RLYB116, Subcutaneously Injected C5 Inhibitor
RLYBRallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
RLYBNEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor. Additionally, Rallybio announced that the initial indicat
Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
RLYBNEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of dosing in a Phase 1 confirmatory pharmacokinetic/pharmacodynamic (PK/PD) study evaluating RLYB116, the Company’s innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor. Additionally, Rallybio announced that the initial indicat
Rallybio Q1 EPS $(0.21) Beats $(0.26) Estimate, Sales $212.00K
RLYBJones Trading Downgrades Rallybio to Hold
RLYBHC Wainwright & Co. Downgrades Rallybio to Neutral
RLYBRallybio Stock Plunges After Program For Pediatric Bleeding Disorder Disappoints
RLYBRallybio ends RLYB212 trial for FNAIT; shifts focus to RLYB116 and preclinical assets with 2025 trial milestones and $6 billion market potential.
Rallybio to Discontinue Development Of RLYB212 In Prevention Of FNAIT, Says RLYB212 Phase 2 PK Results Did Not Achieve Target Concentrations, Including Minimum Target Concentration Required for Efficacy
RLYBHC Wainwright & Co. Reiterates Buy on Rallybio, Maintains $5 Price Target
RLYBRallybio Q4 EPS $(0.25) Beats $(0.29) Estimate, Sales $38.00K Miss $75.00K Estimate
RLYBHC Wainwright & Co. Reiterates Buy on Rallybio, Maintains $5 Price Target
RLYBHC Wainwright & Co. Reiterates Buy on Rallybio, Maintains $5 Price Target
RLYBRallybio Highlights 2024 Achievements; Announces 2025 Milestones, RLYB212 Phase 2 Participant Dosing In Q2 2025, RLYB116 PK/PD Study Launch In Q2 2025, REV102 IND-Enabling Studies Planned For 2025; FNAIT Study Screening To Conclude January 2025.
RLYB